InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M All-Stock Deal

Aethlon Medical to Merge with North Immunology

September 17, 2026

Biotechnology

Aethlon Medical entered into a definitive all-stock merger agreement with North Immunology; after closing, the combined company is expected to operate as North Immunology and trade on Nasdaq. The transaction is paired with an oversubscribed private placement expected to raise approximately $180 million to fund development of North’s NOR-101 program and operations into the second half of 2028.

Lisata Therapeutics Acquires Marea Therapeutics

September 17, 2026

Biotechnology

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction, exchanging Marea equity for Lisata common and preferred shares. The acquisition gives Lisata control of Marea’s clinical-stage cardioendocrine drug pipeline, including candidates for severe hypertriglyceridemia and acromegaly; a concurrent $225 million private placement will fund development of the programs.

Werewolf Therapeutics and Ambros Therapeutics Merge in $150M PIPE to Advance Neridronate Phase 3

August 23, 2026

Pharmaceuticals

Werewolf Therapeutics and Ambros Therapeutics entered into a definitive all-stock merger agreement, with a concurrently announced, oversubscribed $150 million private placement expected to fund development of neridronate through pivotal Phase III results and a planned FDA submission. The combined company will operate as Ambros Therapeutics, be headquartered in San Diego, and is expected to trade on Nasdaq as AMBX.

Liminatus Pharma Proposed Merger to Acquire InnocsAI for $320M in Stock

May 21, 2026

Healthcare Services

Liminatus Pharma has entered into a definitive merger agreement to acquire InnocsAI via a newly formed wholly owned Delaware subsidiary. The deal values InnocsAI at approximately $320 million, with InnocsAI’s members receiving 1.6 billion Liminatus shares at $0.20 per share plus contingent value rights (CVRs) tied to 20% of future net proceeds from certain strategic transactions involving the acquired assets.

CorMedix Acquires Melinta Therapeutics for $300 Million

August 7, 2025

Biotechnology

CorMedix Inc. has entered into a definitive agreement to acquire Melinta Therapeutics, paying $300 million upfront (including $260 million cash and $40 million in CorMedix equity to Melinta shareholders), plus up to $25 million in a regulatory milestone and tiered royalties. The deal is expected to close in September, subject to customary closing conditions and U.S. regulatory approval.

MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger

February 24, 2023

Pharmaceuticals

MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. entered into a definitive merger agreement for an all-stock transaction to form a combined clinical-stage oncology company. The merged organization will advance a pipeline of three clinical-stage oncology drug candidates, including eganelisib, voruciclib, and ME-344.